predictive factors on clinical response to intravitreal Bevacizumab injection in patient with diabetic macular edema

Not Applicable

Completed

• Conditions: diabetic macular edema; diabetic retinopathy; bevacizumab; anti- VEGF; intravitreal therapy

• Registration Number: TCTR20200928001
• Lead Sponsor: Khon Kean university

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-12-01
• Study Start: 2020-09-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 234

Inclusion Criteria

1. diabetic macular edema treated with intravitreal bevacizumab injection
2. older than 18 years old
3. initial visual acuity less than or equal to 6/12.

Exclusion Criteria

1. Diabetic mellitus type I
2. previous vitrectomy or gas injection, previous treatment with focal laser or intravitreal anti-VEGF or intravitreal corticosteroid injection
3. presence of significant media opacity (e.g., mature cataract, vitreous hemorrhage or corneal scar), and co-existing with macular disease (e.g., age related macular degeneration, vascular occlusive disease.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
predictive factors on clinical response; age,sex,laterality,duration of DM,insulin used,FBS,HbA1C march 2019 to december 2019 correction all data from medical record and divided in 2 group by best corrected visual acuity and c

Secondary Outcome Measures

Name	Time	Method
Best corrected visual acuity (BCVA) and central subfoveal thickness improvement after treatment march 2019 to december 2019 best corrected visual acuity by snellen chart and central subfoveal thickness from OCT at first vis